Youlife Group Inc. announced a $2.7 million registered direct offering of 9% senior original issue discount convertible promissory notes, with potential to raise up to $12 million. The notes mature in 12 months and can convert into up to 65.5 million Class A shares, providing the company with capital for working capital and general corporate purposes. The offering is backed by a shelf registration effective in October 2026 and is expected to close around November 3, 2026. This funding supports Youlife's ongoing efforts to modernize blue-collar employment through technology and training across China.
Youlife Group Inc. announced a $2.7 million convertible note offering with potential to raise up to $12 million. For readers following Financials, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: out of 142 priced Financials-sector US stocks, 96 rose and 46 fell. Notable movers include NWG at USD 16.54 (+6.85%), BMNR at USD 21.88 (+6.58%), and BN at USD 43.25 (+6.42%), with typical hold times ranging from 5 to 14 days.
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, focusing on de-risked, post-proof-of-concept assets. The company offers investors exposure to blockbuster therapies with attractive risk-adjusted returns, including aro...
